SWOG clinical trial number
S0715

Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane Induced Neuropathy

Closed
Phase
Accrual
100%
Published
Abbreviated Title
ALC
Activated
09/15/2009
Closed
02/01/2011
Participants
NCORP, Members, Medical Oncologists, Affiliates

Research committees

Symptom Control and Quality of Life
Breast Cancer
Cancer Survivorship
Molecular Epidemiology

Treatment

Acetyl L-Carnitine

Eligibility Criteria Expand/Collapse

Women w/ histologically confirmed primary invasive carcinoma of the breast, Stage I, II or III who have undergone definitive surgery (modified radical mastectomy or breast sparing surgery); recovered from side effects of breast surgery; planning to receive one of the standard taxane-containing regimens as specified in the protocol; concurrent biologic therapy allowed; adequate renal function with serum creatinine </= 2.5 x IULM; participation in other trials o.k.; able and willing to complete questionnaires in English or Spanish; completion of baseline questionnaires within 14 days of registration; age >/= 18 years; Zubrod PS 0-2.

1.0 Cancer Control Credit

Pre- and Post-treatment questionnaires: to track speed of download, right click on the file and choose "Save Target As" option.

Publication Information Expand/Collapse

2018

Two-Year Trends Of Taxane-Induced Neuropathy In Women Enrolled In A Randomized Trial Of Acetyl-L-Carnitine (SWOG S0715)

DL Hershman;JM Unger;K Crew;C Till;H Greenlee;L Minasian;C Moinpour;DL Lew;L Fehrenbacher;JL Wade;S-F Wong;M Fisch;KS Albain Journal of the National Cancer Institute Jun 1;110(6):669-676; 2018 Jan 18. doi: 10.1093/jnci/djx259. [Epub ahead of print]

PMid: PMID29361042 | PMC number: PMC6005110

2017

Two-year trends and predictors of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG S0715; NCT00775645) (http://abstracts.asco.org/199/AbstView_199_184547.html)

DL Hershman;JM Unger;KD Crew;C Ebnesajjad;H Greenlee;C Moinpour;L Minasian;D Lew;JL Wade;KS Albain;MJ Fisch;NL Henry J Clin Oncol 35, 2017 (suppl; abstr 10093);American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster

2014

Enhancing nurse contributions to SWOG clinical trials

L Hansen;C Moinpour;R Ermete Seminars in Nursing Oncology 30(1):26-31;

PMid: PMID24559777 | PMC number: PMC3961058

2013

Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for the prevention of taxane induced neuropathy in women undergoing adjuvant breast cancer therapy

D Hershman;J Unger;K Crew;L Minasian;C Moinpour;L Hansen;DL Lew;L Fehrenbacher;JL Wade;S Wong;G Hortobagyi;F Meyskens;K Albain Journal of Clinical Oncology 31(20):2627-2633;

PMid: PMID23733756 | PMC number: PMC3699727

2012

SWOG S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy

DL Hershman;J Unger;K Crew;C Moinpour;L Minasian;L Hansen;D Lew;P O'Kane;J Wade;S Wong;G Hortobagyi;F Meyskens;K Albain Journal of Clinical Oncology 30 (suppl; abstr 9018);American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion (DH unsuccessfully appealed for oral);

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase